Establishing Liposome-Immobilized Dexamethasone-Releasing PDMS Membrane for the Cultivation of Retinal Pigment Epithelial Cells and Suppression of Neovascularization

Age-related macular degeneration (AMD) is the eye disease with the highest epidemic incidence, and has great impact on the aged population. Wet-type AMD commonly has the feature of neovascularization, which destroys the normal retinal structure and visual function. So far, effective therapy options for rescuing visual function in advanced AMD patients are highly limited, especially in wet-type AMD, in which the retinal pigmented epithelium and Bruch’s membrane structure (RPE-BM) are destroyed by abnormal angiogenesis. Anti-VEGF treatment is an effective remedy for the latter type of AMD; however, it is not a curative therapy. Therefore, reconstruction of the complex structure of RPE-BM and controlled release of angiogenesis inhibitors are strongly required for sustained therapy. The major purpose of this study was to develop a dual function biomimetic material, which could mimic the RPE-BM structure and ensure slow release of angiogenesis inhibitor as a novel therapeutic strategy for wet AMD. We herein utilized plasma-modified polydimethylsiloxane (PDMS) sheet to create a biomimetic scaffold mimicking subretinal BM. This dual-surface biomimetic scaffold was coated with laminin and dexamethasone-loaded liposomes. The top surface of PDMS was covalently grafted with laminin and used for cultivation of the retinal pigment epithelial cells differentiated from human induced pluripotent stem cells (hiPSC-RPE). To reach the objective of inhibiting angiogenesis required for treatment of wet AMD, the bottom surface of modified PDMS membrane was further loaded with dexamethasone-containing liposomes via biotin-streptavidin linkage. We demonstrated that hiPSC-RPE cells could proliferate, express normal RPE-specific genes and maintain their phenotype on laminin-coated PDMS membrane, including phagocytosis ability, and secretion of anti-angiogenesis factor PEDF. By using in vitro HUVEC angiogenesis assay, we showed that application of our membrane could suppress oxidative stress-induced angiogenesis, which was manifested in decreased secretion of VEGF by RPE cells and suppression of vascularization. In conclusion, we propose modified biomimetic material for dual delivery of RPE cells and liposome-enveloped dexamethasone, which can be potentially applied for AMD therapy.

[1]  P. D. de Jong,et al.  Increased expression of angiogenic growth factors in age-related maculopathy , 1997, The British journal of ophthalmology.

[2]  A. Bird,et al.  Therapeutic targets in age-related macular disease. , 2010, The Journal of clinical investigation.

[3]  P. Luthert,et al.  Oxidative stress affects the junctional integrity of retinal pigment epithelial cells. , 2004, Investigative ophthalmology & visual science.

[4]  C. Mailhos,et al.  Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. , 2006, The American journal of pathology.

[5]  M. Nordlund,et al.  Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. , 2019, Journal of cataract and refractive surgery.

[6]  Usha Chakravarthy,et al.  Clinical classification of age-related macular degeneration. , 2013, Ophthalmology.

[7]  G. Storm,et al.  Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo , 2015, The Prostate.

[8]  S. Antimisiaris,et al.  Dexamethasone Incorporating Liposomes: Effect of Lipid Composition on Drug Trapping Efficiency and Vesicle Stability , 2007, Drug delivery.

[9]  S. Bakri,et al.  Review of Combination Therapies for Neovascular Age-Related Macular Degeneration , 2011, Seminars in ophthalmology.

[10]  N. Vakalis,et al.  Intravitreal Combination of Dexamethasone Sodium Phosphate and Bevacizumab in The Treatment of Exudative AMD , 2015, Scientific Reports.

[11]  R. Olabisi,et al.  Scaffolds for retinal pigment epithelial cell transplantation in age-related macular degeneration , 2017, Journal of tissue engineering.

[12]  S. Chiou,et al.  Expression profiling of cell-intrinsic regulators in the process of differentiation of human iPSCs into retinal lineages , 2018, Stem Cell Research & Therapy.

[13]  P. Rosenfeld,et al.  Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies , 2015, The Lancet.

[14]  C. Regillo,et al.  Preferred therapies for neovascular age-related macular degeneration , 2012, Current opinion in ophthalmology.

[15]  Adnan Tufail,et al.  Phase 1 clinical study of an embryonic stem cell–derived retinal pigment epithelium patch in age-related macular degeneration , 2018, Nature Biotechnology.

[16]  Mark S. Humayun,et al.  A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration , 2018, Science Translational Medicine.

[17]  Takashi Daimon,et al.  Autologous Induced Stem‐Cell–Derived Retinal Cells for Macular Degeneration: Brief Report , 2017, The New England journal of medicine.

[18]  Benjamin J. Thomas,et al.  Simultaneous Dexamethasone Intravitreal Implant and Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration Resistant to Anti-VEGF Monotherapy , 2017, Journal of vitreoretinal diseases.

[19]  A. Ahuja,et al.  Subretinal implantation of retinal pigment epithelial cells derived from human embryonic stem cells: improved survival when implanted as a monolayer. , 2013, Investigative ophthalmology & visual science.

[20]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[21]  B. Kuppermann,et al.  Corticosteroids and Anti-Complement Therapy in Retinal Diseases. , 2016, Handbook of experimental pharmacology.

[22]  Jennifer I. Lim,et al.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.

[23]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[24]  W. Amoaku,et al.  Dexamethasone reverses the effects of high glucose on human retinal endothelial cell permeability and proliferation in vitro. , 2016, Experimental eye research.

[25]  A. Pinna,et al.  Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study , 2018, Journal of ophthalmology.

[26]  Y. Tai,et al.  Microdevice-based cell therapy for age-related macular degeneration. , 2014, Developments in ophthalmology.

[27]  J. Roider,et al.  Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differently regulated by different Mitogen-activated protein kinases , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[28]  P. Dubruel,et al.  Generation of hESC-derived retinal pigment epithelium on biopolymer coated polyimide membranes. , 2012, Biomaterials.

[29]  S. Chiou,et al.  Corneal repair by human corneal keratocyte-reprogrammed iPSCs and amphiphatic carboxymethyl-hexanoyl chitosan hydrogel. , 2012, Biomaterials.

[30]  S. Chiou,et al.  Laminin modification subretinal bio-scaffold remodels retinal pigment epithelium-driven microenvironment in vitro and in vivo , 2016, Oncotarget.